For research use only. Not for therapeutic Use.
NSC-370284 is a selective inhibitor of ten-eleven translocation 1 (TET1) and 5-hydroxymethylcytosine (5hmC). NSC-370284 significantly inhibits the level of TET1 expression via targets STAT3/5[1].
NSC-370284 (0-500 nM; 24 h or 48 h) inhibits the viability of MONOMAC-6, THP-1, KOCL-48 and KASUMI-1 acute myeloid leukemia (AML) cells via targeting STAT3/5. NSC-370284 significantly down-regulates the level of TET1 transcription[1].
NSC-370284 (2.5 mg/kg; i.p., once daily for 10 days) improves the pathological morphologies in peripheral blood (PB), bone marrow (BM), spleen, and liver tissues in MLL-AF9 acute myeloid leukemia (AML) mice model[1].
| Catalog Number | I042031 |
| CAS Number | 116409-29-1 |
| Synonyms | 6-[pyrrolidin-1-yl-(3,4,5-trimethoxyphenyl)methyl]-1,3-benzodioxol-5-ol |
| Molecular Formula | C21H25NO6 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H25NO6/c1-24-18-8-13(9-19(25-2)21(18)26-3)20(22-6-4-5-7-22)14-10-16-17(11-15(14)23)28-12-27-16/h8-11,20,23H,4-7,12H2,1-3H3 |
| InChIKey | QCXGNLZKUHBIHD-UHFFFAOYSA-N |
| SMILES | COC1=CC(=CC(=C1OC)OC)C(C2=CC3=C(C=C2O)OCO3)N4CCCC4 |
| Reference | [1]. Jiang X, et al. Targeted inhibition of STAT/TET1 axis as a therapeutic strategy for acute myeloid leukemia. Nat Commun. 2017 Dec 13;8(1):2099. |
